CGAS and Hepatic fibrosis: Atractylenolide III (ATR III) mitigates liver fibrosis by suppressing the cGAS/NF-κB pathway in HSCs, which subsequently inhibits the senescent cell-derived senescence-associated secretory phenotype (SASP) and decreases inflammation (55).